Telomir Pharmaceuticals Changes HQ, Reports Officer Compensation
Ticker: TELO · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1971532
Sentiment: neutral
Topics: corporate-governance, executive-compensation, office-relocation
TL;DR
Telomir Pharma moved its HQ to Baltimore, MD. New exec comp details and director elections filed.
AI Summary
Telomir Pharmaceuticals, Inc. announced on June 18, 2024, a change in its principal executive offices to Baltimore, Maryland. The company also reported on compensatory arrangements for certain officers and the election of directors. The filing details the company's principal executive office address change and related corporate governance matters.
Why It Matters
This filing indicates a significant operational shift for Telomir Pharmaceuticals with a new principal executive office location, which could impact its operational focus and accessibility.
Risk Assessment
Risk Level: low — The filing primarily concerns corporate governance and administrative changes, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
- Baltimore, Maryland (location) — New Principal Executive Offices
- Florida (location) — State of Incorporation
FAQ
What is the new address for Telomir Pharmaceuticals' principal executive offices?
The new address for Telomir Pharmaceuticals' principal executive offices is 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on June 18, 2024.
What are the main topics covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
In which state was Telomir Pharmaceuticals, Inc. originally incorporated?
Telomir Pharmaceuticals, Inc. was incorporated in Florida.
What is the IRS Employer Identification Number for Telomir Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Telomir Pharmaceuticals, Inc. is 87-2606031.
Filing Stats: 1,191 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2024-06-21 17:38:04
Key Financial Figures
- $62,500 — s from the date thereof an aggregate of $62,500 in equal installments over three months
- $137,500 — ployment Agreement, Ms. Yanez will earn $137,500 per year. Ms. Yanez shall also be entit
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex10-1.htm (EX-10.1) — 57KB
- 0001493152-24-024812.txt ( ) — 294KB
- telo-20240618.xsd (EX-101.SCH) — 3KB
- telo-20240618_lab.xml (EX-101.LAB) — 33KB
- telo-20240618_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Nathan Fuentes On June 18, 2024, Telomir Pharmaceuticals, Inc. (the " Company ") and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the " Separation Agreement ") whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes' employment as a Chief Financial Officer of the Company would end as of June 18, 2024. Provided that Mr. Fuentes does not revoke the acceptance of the Separation Agreement and complies with the terms therein, the Company shall (i) pay Mr. Fuentes from the date thereof an aggregate of $62,500 in equal installments over three months on the Company' regular payroll schedule and (ii) permit any options granted to Mr. Fuentes for the purchase of shares of Company stock pursuant to the Company's 2023 Omnibus Incentive Plan to remain exercisable until the expiration date set in such option grants. The resignation of Mr. Fuentes was not based on any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Appointment of Michelle Yanez Michelle Yanez, MBA On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company. Below is Ms. Yanez's biography: Michelle Yanez, MBA has served as our part-time Corporate Controller since May 2022. Ms. Yanez has served as the Chief Financial Officer of MIRA Pharmaceuticals, Inc., a publicly traded pre-clinical-stage pharmaceutical company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders (Nasdaq: MIRA) since May 2023. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies. Ms. Yanez' experience includes a broad range of responsi
Financial Statements and
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed with this Current Report on Form 8-K: Exhibit No. Description 10.1 Employment Agreement by and between the Company and Michelle Yanez, dated June 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: June 21, 2024 By: /s/ Christopher Chapman, Jr., MD Christopher Chapman, Jr., MD Chief Executive Officer